Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Dec;13(12):697-698.
doi: 10.1038/nrendo.2017.136. Epub 2017 Oct 13.

Bone diseases: Romosozumab - on track or derailed?

Affiliations
Comment

Bone diseases: Romosozumab - on track or derailed?

Sundeep Khosla. Nat Rev Endocrinol. 2017 Dec.

Abstract

Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The author declares no competing interests.

Comment on

References

    1. Khosla S & Hofbauer LC Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 10.1016/s2213-8587(17)30188-2 (2017). - DOI - PMC - PubMed
    1. Brunkow ME et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot‑containing protein. Am. J. Hum. Genet 68, 577–589 (2001). - PMC - PubMed
    1. Khosla S, Westendorf JJ & Oursler MJ Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest 118, 421–428 (2008). - PMC - PubMed
    1. Li X et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res 24, 578–588 (2009). - PubMed
    1. McClung MR et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med 370, 412–420 (2014). - PubMed

Publication types